HDAC9 and diffuse large B-cell lymphoma: To improve the anti-tumor efficacy of SHR2554 in EZH2 wild-type cell lines, synergistic anti-tumor activity of HDAC inhibitor HBI8000 and EZH2 inhibitor SHR2554 was next explored in DLBCL cell lines, especially for those without EZH2 mutation.